Who is sponsoring NCT02853214?

NCT02853214 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT02853214?

Interventions in NCT02853214: Genetic analysis of peripheral blood samples.

What condition does NCT02853214 study?

NCT02853214 studies Dysglobulinemia.

Is NCT02853214 still recruiting?

NCT02853214 is currently completed. Last updated 3 September 2025.

Last reviewed 2025-09-03 · How we verify

NCT02853214: PreFamDys

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Familial Dysglobulinemia

Completed NA Last updated 3 September 2025

What this trial tests

NA trial testing Genetic analysis of peripheral blood samples in Dysglobulinemia in 1,868 participants. Completed in 25 September 2023.

Timeline

6 February 2008

Primary endpoint
25 September 2023

25 September 2023

Quick facts

Lead sponsor	Hospices Civils de Lyon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	1,868
Start date	6 February 2008
Primary completion	25 September 2023
Estimated completion	25 September 2023
Sites	47 locations across France

Drugs / interventions tested

Genetic analysis of peripheral blood samples

Conditions studied

Dysglobulinemia — all drugs for Dysglobulinemia →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Dysglobulinemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple Myeloma (MM) is a malignant proliferation of monoclonal plasma cells. Myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. Myeloma commonly evolves from a precursor disease, Monoclonal gammopathy of undetermined significance (MGUS). Despite intensive study, the etiology of MGUS and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of MM, MGUS or the transition between the two. The overall goal is to identify risk genes for dysglobulinemia, and more specifically Multiple Myeloma. This will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. Material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study.
Dumontet C, Demangel D, Galia P, Karlin L, et al · · 2023 · cited 5× · PMID 36588407 · DOI 10.1002/ajh.26785

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02853214 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 3 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02853214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing